유전체 시퀀싱 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 염기 배열별, 기술별, 용도별, 최종 사용자별, 지역별 및 경쟁(2021-2031년)

The global genome sequencing market is poised for significant expansion, projected to reach USD 71.54 Billion by 2031 from USD 20.55 Billion in 2025, demonstrating a 23.11% CAGR. This growth is primarily fueled by decreasing sequencing costs and the increasing integration of genomic data into precision medicine for personalized treatments. The ongoing stewardship of millions of genomes by organizations like the Global Alliance for Genomics and Health further highlights the growing adoption and utility of sequencing technologies in global health.\nHowever, this robust growth is tempered by substantial challenges related to data privacy and the ethical handling of sensitive genetic information. The need for secure storage and strict regulatory compliance for the vast amounts of genomic data introduces operational complexities, potentially hindering the smooth implementation of sequencing workflows in clinical settings.

Market Driver

The genome sequencing market is primarily driven by the increasing global incidence of cancer and rare genetic disorders, which demand advanced diagnostic and therapeutic approaches. Clinicians' growing reliance on genomic profiles for precision medicine in oncology and rare disease management has significantly amplified the need for sequencing, evidenced by projections such as over 2,041,000 new cancer cases in the United States in 2025. This substantial disease burden highlights the crucial requirement for scalable sequencing solutions to facilitate personalized treatment and enhance patient outcomes worldwide.\nConcurrently, the ongoing reduction in sequencing costs and enhanced accessibility are making genomic data more widely available, fostering population-scale biobanking and expanded clinical integration. Technological advancements have lowered financial hurdles, enabling large-scale research initiatives, as demonstrated by the successful analysis of nearly half a million whole genomes from the UK Biobank, while government investments, such as the UK's £520 million allocation for life sciences manufacturing, further bolster accessible sequencing infrastructure.

Market Challenge

A significant challenge impeding the global genome sequencing market's growth is the critical need for robust data privacy management and ethical handling of sensitive genetic information. With escalating sequencing volumes, the potential for data breaches and unauthorized access to personal genomic data increases, demanding stringent security measures that complicate data sharing and storage. Organizations must navigate complex international regulations, leading to operational delays and higher compliance costs, which in turn hinder the smooth incorporation of sequencing into clinical workflows.\nThese privacy and security concerns are substantial, with 41% of life science professionals identifying them as a major barrier to adopting digital laboratory technologies in 2024. This apprehension underscores the difficulty market participants face in balancing the clinical utility of genomic data with the essential requirement to protect patient confidentiality, ultimately diverting resources from innovation and slowing market expansion.

Market Trends

The integration of Artificial Intelligence and Machine Learning for automated genomic data analysis is profoundly transforming the market by addressing the critical bottleneck of data interpretation. As sequencing throughput increases, the overwhelming volume of raw data necessitates algorithmic solutions for rapid variant calling and clinical annotation, significantly reducing turnaround times for diagnostics and enabling near real-time applications in critical care. For example, AI integration in Illumina's DRAGEN v4.4 software enhanced structural variant calling accuracy by 30%, improving the clinical utility of genomic results.\nConcurrently, the accelerated adoption of third-generation long-read sequencing technologies is expanding the market by overcoming the limitations of traditional short-read platforms. These technologies allow for sequencing long DNA stretches without fragmentation, enabling precise detection of large structural variants and complex repetitive regions previously missed. This technical advantage is fueling strong commercial demand across research and clinical sectors seeking comprehensive genomic maps, evidenced by Oxford Nanopore Technologies' 11% revenue increase, reflecting global demand for its nanopore-based long-read sequencing solutions.

Key Market Players

• Illumina, Inc
• Thermo Fisher Scientific Inc
• F. Hoffmann-La Roche Ltd
• Oxford Nanopore Technologies plc
• BGI Genomics Co., Ltd
• QIAGEN N.V
• Pacific Biosciences of California, Inc
• PerkinElmer, Inc
• Agilent Technologies, Inc
• Macrogen, Inc

Report Scope

In this report, the Global Genome Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genome Sequencing Market, By Nucleotide Sequenced

• DNA
• RNA

Genome Sequencing Market, By Technique

• Next Generation Sequencing
• PCR
• Microarray Technology
• Others

Genome Sequencing Market, By Application

• Diagnostics
• Drug Discovery & Development
• Precision Medicine
• Others

Genome Sequencing Market, By End User

• Academic & Research Institutions
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• Others

Genome Sequencing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genome Sequencing Market.

Available Customizations:

Global Genome Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genome Sequencing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Nucleotide Sequenced (DNA v/s RNA)
  • 5.2.2. By Technique (Next Generation Sequencing, PCR, Microarray Technology, Others)
  • 5.2.3. By Application (Diagnostics, Drug Discovery & Development, Precision Medicine, Others)
  • 5.2.4. By End User (Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Genome Sequencing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Nucleotide Sequenced
  • 6.2.2. By Technique
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genome Sequencing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Nucleotide Sequenced
      • 6.3.1.2.2. By Technique
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Genome Sequencing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Nucleotide Sequenced
      • 6.3.2.2.2. By Technique
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Genome Sequencing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Nucleotide Sequenced
      • 6.3.3.2.2. By Technique
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Genome Sequencing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Nucleotide Sequenced
  • 7.2.2. By Technique
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genome Sequencing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Nucleotide Sequenced
      • 7.3.1.2.2. By Technique
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Genome Sequencing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Nucleotide Sequenced
      • 7.3.2.2.2. By Technique
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Genome Sequencing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Nucleotide Sequenced
      • 7.3.3.2.2. By Technique
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Genome Sequencing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Nucleotide Sequenced
      • 7.3.4.2.2. By Technique
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Genome Sequencing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Nucleotide Sequenced
      • 7.3.5.2.2. By Technique
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Genome Sequencing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Nucleotide Sequenced
  • 8.2.2. By Technique
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Genome Sequencing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Nucleotide Sequenced
      • 8.3.1.2.2. By Technique
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Genome Sequencing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Nucleotide Sequenced
      • 8.3.2.2.2. By Technique
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Genome Sequencing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Nucleotide Sequenced
      • 8.3.3.2.2. By Technique
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Genome Sequencing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Nucleotide Sequenced
      • 8.3.4.2.2. By Technique
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Genome Sequencing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Nucleotide Sequenced
      • 8.3.5.2.2. By Technique
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Genome Sequencing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Nucleotide Sequenced
  • 9.2.2. By Technique
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Genome Sequencing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Nucleotide Sequenced
      • 9.3.1.2.2. By Technique
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Genome Sequencing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Nucleotide Sequenced
      • 9.3.2.2.2. By Technique
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Genome Sequencing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Nucleotide Sequenced
      • 9.3.3.2.2. By Technique
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Genome Sequencing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Nucleotide Sequenced
  • 10.2.2. By Technique
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Genome Sequencing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Nucleotide Sequenced
      • 10.3.1.2.2. By Technique
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Genome Sequencing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Nucleotide Sequenced
      • 10.3.2.2.2. By Technique
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Genome Sequencing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Nucleotide Sequenced
      • 10.3.3.2.2. By Technique
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Genome Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Illumina, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. Oxford Nanopore Technologies plc
• 15.5. BGI Genomics Co., Ltd
• 15.6. QIAGEN N.V
• 15.7. Pacific Biosciences of California, Inc
• 15.8. PerkinElmer, Inc
• 15.9. Agilent Technologies, Inc
• 15.10. Macrogen, Inc

16. Strategic Recommendations

17. About Us & Disclaimer